MCID: INT064
MIFTS: 55

Intermediate Uveitis

Categories: Eye diseases, Rare diseases

Aliases & Classifications for Intermediate Uveitis

MalaCards integrated aliases for Intermediate Uveitis:

Name: Intermediate Uveitis 12 59 15
Uveitis, Intermediate 44 73
Peripheral Uveoretinitis 12
Uveitis Intermediate 55
Chronic Cyclitis 12
Iu 59

Characteristics:

Orphanet epidemiological data:

59
intermediate uveitis
Inheritance: Not applicable; Age of onset: Childhood; Age of death: normal life expectancy;

Classifications:

MalaCards categories:
Global: Rare diseases
Anatomical: Eye diseases
Orphanet: 59  
Rare eye diseases


External Ids:

Disease Ontology 12 DOID:12732
MeSH 44 D015867
NCIt 50 C35110
Orphanet 59 ORPHA279914
ICD10 via Orphanet 34 H30.2
UMLS via Orphanet 74 C0042166
UMLS 73 C0042166

Summaries for Intermediate Uveitis

MalaCards based summary : Intermediate Uveitis, also known as uveitis, intermediate, is related to cervicitis and acute disseminated encephalomyelitis. An important gene associated with Intermediate Uveitis is IL2RA (Interleukin 2 Receptor Subunit Alpha), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Azathioprine and Infliximab have been mentioned in the context of this disorder. Affiliated tissues include eye, retina and endothelial, and related phenotypes are cardiovascular system and hematopoietic system

Wikipedia : 76 Intermediate uveitis is a form of uveitis localized to the vitreous and peripheral retina. Primary sites... more...

Related Diseases for Intermediate Uveitis

Diseases in the Uveitis family:

Posterior Uveitis Intermediate Uveitis
Infectious Anterior Uveitis Anterior Uveitis
Infectious Posterior Uveitis

Diseases related to Intermediate Uveitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 331)
# Related Disease Score Top Affiliating Genes
1 cervicitis 30.2 IL2 IL2RA
2 acute disseminated encephalomyelitis 30.0 HLA-B IL10
3 choroiditis 30.0 IL10 TNF
4 panuveitis 29.9 HLA-B IL10 TNF
5 posterior uveitis 29.5 IFNG IL2 IL2RA TNF
6 rubella 29.2 HLA-B IL10 TNF
7 uveitis 29.1 CXCR3 HLA-B IFNG IL10 IL2RA TNF
8 alopecia areata 28.8 IFNG IL2 IL2RA TNF
9 pneumonia 28.3 IL10 IL6 TNF
10 crohn's disease 28.3 IL10 IL6 TNF
11 aphthous stomatitis 27.8 HLA-B IL10 IL6 TNF
12 dermatitis, atopic 27.2 CXCR3 IFNG IL10 IL2 IL2RA TNF
13 multiple sclerosis 26.4 CXCR3 IFNG IL10 IL2 IL2RA IL6
14 brucellosis 26.3 IFNG IL10 IL2 IL2RA IL6 TNF
15 autoimmune disease 25.0 CXCR3 HLA-B IFNG IL10 IL2 IL2RA
16 congenital disorder of glycosylation, type iu 12.2
17 pars planitis 12.0
18 rickets 11.4
19 epileptic encephalopathy, early infantile, 36 11.3
20 factor xi deficiency 11.0
21 folliculitis 10.6 IFNG IL2RA
22 toxic oil syndrome 10.6 IFNG IL2RA
23 ileocolitis 10.5 IL2RA TNF
24 hypersplenism 10.5 IFNG IL2RA
25 idiopathic bronchiectasis 10.5 HLA-B IFNG
26 histoplasmosis 10.5 HLA-B IFNG
27 nonspecific interstitial pneumonia 10.5 CXCR3 IFNG
28 septic arthritis 10.5 CXCR3 IFNG
29 variola major 10.5 IFNG IL2
30 staphylococcal toxic shock syndrome 10.5 IFNG TNF
31 fixed drug eruption 10.4 IFNG IL2
32 berylliosis 10.4 IFNG IL2
33 trichosporonosis 10.4 IFNG TNF
34 chronic beryllium disease 10.4 IFNG TNF
35 nontuberculous mycobacterial lung disease 10.4 HLA-B TNF
36 atopic keratoconjunctivitis 10.4 IFNG IL2
37 alveolar echinococcosis 10.4 HLA-B TNF
38 oral tuberculosis 10.4 IL2 TNF
39 soft tissue sarcoma 10.4 IFNG TNF
40 tuberculous peritonitis 10.3 IFNG TNF
41 pustulosis palmaris et plantaris 10.3 CXCR3 TNF
42 sporotrichosis 10.3 IFNG IL10
43 vulvovaginal candidiasis 10.3 IFNG IL2
44 baylisascariasis 10.3 IFNG IL10
45 farmer's lung 10.3 IL2 TNF
46 pericardial tuberculosis 10.3 IFNG IL10
47 tuberculoid leprosy 10.3 IFNG IL10
48 pleural tuberculosis 10.3 IFNG TNF
49 limited scleroderma 10.3 IL2 IL2RA
50 buruli ulcer 10.2 IFNG IL10

Graphical network of the top 20 diseases related to Intermediate Uveitis:



Diseases related to Intermediate Uveitis

Symptoms & Phenotypes for Intermediate Uveitis

MGI Mouse Phenotypes related to Intermediate Uveitis:

46 (show all 13)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.07 IFNG IL10 CXCR3 IL2 TGFBR3 TNF
2 hematopoietic system MP:0005397 10.06 IL2RA IL10 IL6 CXCR3 IL2 IFNG
3 cellular MP:0005384 10.05 IL2 IFNG IL10 CXCR3 TGFBR3 TNF
4 immune system MP:0005387 10.03 IL2RA IL10 IL6 CXCR3 IL2 IFNG
5 digestive/alimentary MP:0005381 9.97 IFNG IL2RA IL10 IL2 TNF IL6
6 mortality/aging MP:0010768 9.97 IL2 IFNG IL2RA IL10 CXCR3 TGFBR3
7 endocrine/exocrine gland MP:0005379 9.95 IL2 IFNG IL2RA IL10 TNF IL6
8 liver/biliary system MP:0005370 9.88 IL10 IL2 IFNG TNF IL6 TGFBR3
9 neoplasm MP:0002006 9.73 IL10 IL6 CXCR3 IL2 IFNG TNF
10 muscle MP:0005369 9.72 IFNG IL10 TGFBR3 TNF IL6
11 reproductive system MP:0005389 9.63 IL2 IFNG IL10 TGFBR3 TNF IL6
12 respiratory system MP:0005388 9.5 IL2RA IL10 IL6 CXCR3 IL2 IFNG
13 vision/eye MP:0005391 9.1 IL2 IFNG IL2RA IL10 TNF IL6

Drugs & Therapeutics for Intermediate Uveitis

Drugs for Intermediate Uveitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 97)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Azathioprine Approved Phase 4 446-86-6 2265
2
Infliximab Approved Phase 4,Phase 1,Phase 2 170277-31-3
3
Methotrexate Approved Phase 4,Phase 3,Phase 1,Phase 2 1959-05-2, 59-05-2 126941
4
Mycophenolate mofetil Approved, Investigational Phase 4,Phase 3 128794-94-5 5281078
5
Mycophenolic acid Approved Phase 4,Phase 3 24280-93-1 446541
6
Chlorambucil Approved Phase 4 305-03-3 2708
7
Cyclophosphamide Approved, Investigational Phase 4 50-18-0, 6055-19-2 2907
8
Fluocinolone Acetonide Approved, Investigational, Vet_approved Phase 4,Phase 3,Not Applicable 67-73-2 6215
9
Prednisone Approved, Vet_approved Phase 4,Phase 3 53-03-2 5865
10
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492
11
Dexamethasone Approved, Investigational, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1 50-02-2 5743
12 Anti-Bacterial Agents Phase 4,Phase 3,Phase 2,Phase 1
13 Antibiotics, Antitubercular Phase 4,Phase 3,Phase 2,Phase 1
14 Anti-Infective Agents Phase 4,Phase 3,Phase 1,Phase 2
15 Antimetabolites Phase 4,Phase 3,Phase 1,Phase 2
16 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 1,Phase 2
17 Antirheumatic Agents Phase 4,Phase 3,Phase 1,Phase 2
18 Antitubercular Agents Phase 4,Phase 3
19 Cyclosporins Phase 4
20 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1
21 Alkylating Agents Phase 4
22 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
23 Antineoplastic Agents, Alkylating Phase 4
24 glucocorticoids Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
25 Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
26 Hormones Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
27 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable
28 Adrenocorticotropic Hormone Phase 4,Phase 2
29 beta-endorphin Phase 4,Phase 2
30 Melanocyte-Stimulating Hormones Phase 4,Phase 2
31 Antiemetics Phase 4,Phase 3,Phase 2,Phase 1
32 Antineoplastic Agents, Hormonal Phase 4,Phase 3,Phase 2,Phase 1
33 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1
34 BB 1101 Phase 4,Phase 2,Phase 3,Phase 1
35 Dexamethasone acetate Phase 4,Phase 2,Phase 3,Phase 1 1177-87-3
36 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1
37 HIV Protease Inhibitors Phase 4,Phase 2,Phase 3
38 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
39
protease inhibitors Phase 4,Phase 2,Phase 3
40
Methylprednisolone Approved, Vet_approved Phase 3 83-43-2 6741
41
Prednisolone Approved, Vet_approved Phase 3 50-24-8 5755
42
Adalimumab Approved Phase 3 331731-18-1 16219006
43
Triamcinolone Approved, Vet_approved Phase 3,Phase 1,Phase 2 124-94-7 31307
44
Difluprednate Approved Phase 3 23674-86-4 443936
45
Fluprednisolone Approved Phase 3 53-34-9
46
Folic Acid Approved, Nutraceutical, Vet_approved Phase 3,Phase 1,Phase 2 59-30-3 6037
47
leucovorin Approved, Nutraceutical Phase 3,Phase 1,Phase 2 58-05-9 143 6006
48 Methylprednisolone acetate Phase 3
49 Methylprednisolone Hemisuccinate Phase 3
50 Prednisolone acetate Phase 3

Interventional clinical trials:

(show top 50) (show all 63)
# Name Status NCT ID Phase Drugs
1 Multicenter Uveitis Steroid Treatment (MUST) Trial Completed NCT00132691 Phase 4 fluocinolone acetonide intraocular implant;oral corticosteroid with immunosuppressive agents as needed
2 Study of H.P. ACTHAR Subcutaneous Gelatin (Gel)(Highly Purified Gel Injection) in Uveitis Patients Completed NCT02764697 Phase 4 H.P. ACTHAR SUBCUTANEOUS GEL INJECTION
3 Study of the Effectiveness of Ozurdex for the Control of Uveitis Recruiting NCT02049476 Phase 4 Dexamethasone pellet
4 Myfortic for the Treatment of Non-infectious Intermediate Uveitis Completed NCT01092533 Phase 3 Myfortic;Decortin
5 Randomized, Controlled Trial to Test the Efficacy of Interferon Beta in the Treatment of Intermediate Uveitis Completed NCT00344253 Phase 3 Interferon beta;Methotrexate
6 Efficacy and Safety of Adalimumab in Subjects With Inactive Uveitis Completed NCT01124838 Phase 3 Adalimumab;Prednisone;Placebo
7 A Study of the Safety and Efficacy of a New Treatment for Non-Infectious Intermediate or Posterior Uveitis Completed NCT00333814 Phase 2, Phase 3 Dexamethasone;dexamethasone;Sham injection
8 Efficacy and Safety of Adalimumab in Patients With Active Uveitis Completed NCT01138657 Phase 3 Prednisone;Placebo
9 A Controlled, Multi-center Study of the Utilization and Safety of the MK II Inserter and the Safety of the FAI Insert in Subjects With Non-infectious Uveitis Affecting the Posterior Segment of the Eye Completed NCT02748512 Phase 3 FAI insert
10 Phase III Study in Refractory Behcet's Disease Completed NCT00995709 Phase 3 AIN457;AIN457;Placebo
11 Suprachoroidal Injection of CLS-TA in Subjects Non-infectious Uveitis Completed NCT03097315 Phase 3
12 Suprachoroidal Injection of CLS-TA in Subjects With Macular Edema Associated With Non-infectious Uveitis Completed NCT02595398 Phase 3 4mg CLS-TA Suprachoriodal Injection;Sham Procedure
13 A Study of the Long-term Safety and Efficacy of Adalimumab in Subjects With Intermediate-, Posterior-, or Pan-uveitis Completed NCT01148225 Phase 3 adalimumab
14 Difluprednate Pediatric Study for the Treatment of Inflammation Post-Cataract Surgery Completed NCT01124045 Phase 3 Difluprednate ophthalmic emulsion, 0.05%;Prednisolone acetate ophthalmic suspension, 1.0%
15 A Study of Tocilizumab in Patients With Active Polyarticular Juvenile Idiopathic Arthritis Completed NCT00988221 Phase 3 Tocilizumab;Placebo
16 A Study of LX211 in Clinically Quiescent Non-infectious Intermediate, Anterior and Intermediate, Posterior or Pan-Uveitis Completed NCT00404742 Phase 3 Placebo;LX211;LX211;LX211
17 A Study of LX211 in Active Sight Threatening, Non-infectious Intermediate-, Anterior and Intermediate-, Posterior-, or Pan-Uveitis Completed NCT00404612 Phase 3 Placebo;LX211;LX211;LX211
18 Safety and Efficacy of Difluprednate 0.05% for the Treatment of Anterior Uveitis Completed NCT01201798 Phase 3 Difluprednate 0.05% ophthalmic emulsion;Prednisolone acetate 1.0% ophthalmic suspension
19 Safety and Efficacy Study of a Fluocinolone Acetonide Intravitreal (FAI) Insert in Subjects With Chronic Non-infectious Posterior Uveitis Active, not recruiting NCT02746991 Phase 3 Sham Injection;FAI Insert
20 Safety and Efficacy of an Injectable Fluocinolone Acetonide Intravitreal Insert Active, not recruiting NCT01694186 Phase 3 FAI insert;Sham injection
21 38 Week Extension Study to CAIN457C2303 Terminated NCT01093846 Phase 3 AIN457;AIN457;Placebo AIN457
22 Safety and Efficacy of AIN457 in Patients With Active Non-infectious Uveitis Terminated NCT01095250 Phase 3 AIN457;AIN457;AIN457;Placebo
23 Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis Terminated NCT01032915 Phase 3 Placebo
24 Long-term Safety of Gevokizumab in the Treatment of Patients With Chronic Non-infectious Uveitis (EYEGUARD-X) Terminated NCT02375685 Phase 3
25 Extension Study to Assess Safety and Efficacy of AIN457 in Patients With Active Non-infectious Uveitis Terminated NCT01103024 Phase 3
26 Safety and Efficacy Study of Gevokizumab to Treat Non-infectious Uveitis Controlled With Systemic Treatment Terminated NCT01747538 Phase 3 Placebo;Dose 1 gevokizumab;Dose 2 gevokizumab
27 Safety and Efficacy Study of Gevokizumab to Treat Active Non-infectious Uveitis Terminated NCT01684345 Phase 3 Placebo;Dose 1 gevokizumab;Dose 2 gevokizumab
28 An Open-label, Rollover Study Providing Continued Dosing of Gevokizumab in Order to Assess Long-term Gevokizumab Safety Data Terminated NCT02258854 Phase 3 Dose 2 gevokizumab
29 Safety and Efficacy of AIN457 in Patients With Quiescent Non-infectious Uveitis Terminated NCT01090310 Phase 3 AIN457;Placebo
30 Study to Evaluate the Long Term Use of Treatment With AIN457 for Uveitis Withdrawn NCT01327664 Phase 3
31 Safety, Tolerability, and Efficacy of AEB071 in the Treatment of Uveitis Completed NCT00615693 Phase 2 AEB071
32 Safety,Tolerability and Efficacy of Intravitreal LFG316 in Patients With Active Non-infectious Intermediate-, posterior-or Panuveitis , Completed NCT01526889 Phase 2 LFG316;Conventional Therapy
33 Safety Study of Suprachoroidal Triamcinolone Acetonide Via Microneedle to Treat Uveitis Completed NCT01789320 Phase 1, Phase 2 triamcinolone acetonide (Triesence®)
34 Use of Cross-linked Donor Corneas as Carriers for the Boston Keratoprosthesis Completed NCT01582880 Phase 1, Phase 2 Riboflavin
35 Topical Interferon Gamma for Macular Edema Secondary to Uveitis Completed NCT01376362 Phase 1, Phase 2 Interferon Gamma-1b
36 Suprachoroidal Injection of Triamcinolone Acetonide in Subjects With Macular Edema Following Non-Infectious Uveitis Completed NCT02255032 Phase 2 4 mg CLS-TA;0.8 mg CLS-TA
37 Intravitreal Infliximab in Refractory Uveitis in Behcet's Disease: A Safety and Efficacy Clinical Study Completed NCT02620618 Phase 1, Phase 2 Intravitreal Infliximab
38 Safety and Efficacy of AIN457 in Noninfectious Uveitis Completed NCT00685399 Phase 2 AIN457;AIN 457;AIN457
39 Leflunomide to Treat Uveitis Completed NCT00001863 Phase 2 Leflunomide
40 Intravitreal Sirolimus as Therapeutic Approach to Uveitis Recruiting NCT01280669 Phase 2 Intravitreal injection 440mcg;Intravitreal injection of sirolimus 880mcg
41 Ustekinumab (STELARA) for the Treatment of Active Sight-Threatening Uveitis (STAR Study) Recruiting NCT02911116 Phase 2 Ustekinumab
42 Vision Restoration With a Collagen Crosslinked Boston Keratoprosthesis Unit Recruiting NCT02863809 Phase 1, Phase 2 Riboflavin;Dextran
43 Study of the Safety, Tolerability, and Bioactivity of Tocilizumab On Patients With Non-infectious UVEITIS: The STOP-UVEITIS Study Active, not recruiting NCT01717170 Phase 1, Phase 2 Tocilizumab
44 ACTH as A Re-emerging theRapy for Uveitis (The ACTHAR Study) Not yet recruiting NCT02931175 Phase 2 ACTH gel
45 Safety and Preliminary Efficacy Study of V404 PDS in Uveitis Terminated NCT02125266 Phase 1, Phase 2 V404
46 Safety &Efficacy of CF101 to Subjects With Uveitis Withdrawn NCT01905124 Phase 2 CF101;Placebo
47 A Phase I/IIa Study for the Treatment of Uveitis With Iontophoresis Withdrawn NCT00499551 Phase 1, Phase 2
48 Sirolimus as Therapeutic Approach to Uveitis Unknown status NCT00908466 Phase 1 Sirolimus (rapamycin);Sirolimus (rapamycin)
49 The Treatment of Uveitic Cystoid Macular Edema With Topical Interferon Gamma Completed NCT00943982 Phase 1 Interferon Gamma 1-b
50 Causes of Visual Loss in Retinal Disease Unknown status NCT01613963 Immunosuppressive Agents

Search NIH Clinical Center for Intermediate Uveitis

Cochrane evidence based reviews: uveitis, intermediate

Genetic Tests for Intermediate Uveitis

Anatomical Context for Intermediate Uveitis

MalaCards organs/tissues related to Intermediate Uveitis:

41
Eye, Retina, Endothelial, Testes, T Cells, B Cells

Publications for Intermediate Uveitis

Articles related to Intermediate Uveitis:

(show top 50) (show all 175)
# Title Authors Year
1
Complications in Intermediate Uveitis: Prevalence, Time of Onset, and Effects on Vision in Short-Term and Long-Term Follow-Up. ( 29370567 )
2018
2
Efficacy and Safety of Mycophenolate Mofetil in the Treatment of Recalcitrant Intermediate Uveitis. ( 29652198 )
2018
3
Efficacy of Natalizumab in Intermediate Uveitis Related to Multiple Sclerosis: A Case Report. ( 29452449 )
2018
4
Primary Glomerulonephritis with Unique C4d Deposition and Concurrent Non-infectious Intermediate Uveitis: a Case Report and Literature Review. ( 29713256 )
2018
5
Amblyopia due to intermediate uveitis as the presenting symptom of Crohn's disease in a 6-year-old boy. ( 29102673 )
2017
6
INTERMEDIATE UVEITIS ASSOCIATED WITH PERIODIC FEVER, APHTHOUS STOMATITIS, PHARYNGITIS, AND CERVICAL ADENITIS SYNDROME. ( 28570435 )
2017
7
Preoperative Inflammatory Control and Surgical Outcome of Vitrectomy in Intermediate Uveitis. ( 28465834 )
2017
8
Listeria Monocytogenes Endophthalmitis after Intermediate Uveitis and ppV for Retinal Detachment. ( 28329887 )
2017
9
Re: Niederer etA al.: Predictors of long-term visual outcome in intermediate uveitis (Ophthalmology. 2017;124:393-398). ( 28645347 )
2017
10
A systematic review and economic evaluation of adalimumab and dexamethasone for treating non-infectious intermediate uveitis, posterior uveitis or panuveitis in adults. ( 29183563 )
2017
11
Re: Jaffe etA al.: Injectable fluocinolone acetonide long-acting implant for noninfectious intermediate uveitis, posterior uveitis, and panuveitis: 2-year results (Ophthalmology. 2016;123:1940-1948). ( 28734339 )
2017
12
Ultra-Widefield Fluorescein Angiography in Intermediate Uveitis. ( 29040047 )
2017
13
Disease Remission in Children and Adolescents with Intermediate Uveitis: A Survival Analysis. ( 29241207 )
2017
14
Cystoid Macular Edema in Retinitis Pigmentosa with Intermediate Uveitis Responded Well to Oral and Posterior Subtenon Steroid. ( 28353369 )
2017
15
Re: Jaffe etA al.: Injectable fluocinolone acetonide long-acting implant for noninfectious intermediate uveitis, posterior uveitis, and panuveitis: two-year results (Ophthalmology. 2016;123:1940-1948). ( 28335961 )
2017
16
Association between intermediate uveitis and toxocariasis in the Korean population. ( 28151857 )
2017
17
PERIPHERAL RETINOSCHISIS IN INTERMEDIATE UVEITIS. ( 28590967 )
2017
18
Intermediate uveitis: pattern of etiology, complications, treatment and outcome in a tertiary academic center. ( 28449695 )
2017
19
Enteric-coated mycophenolate sodium in the treatment of non-infectious intermediate uveitis: results of a prospective, controlled, randomised, open-label, early terminated multicentre trial. ( 28903965 )
2017
20
Long-term results of pars plana vitrectomy as an anti-inflammatory therapy of pediatric intermediate uveitis resistant to standard medical treatment. ( 28862736 )
2017
21
Effect of Adalimumab on Visual Functioning in Patients With Noninfectious Intermediate Uveitis, Posterior Uveitis, and Panuveitis in the VISUAL-1 and VISUAL-2 Trials. ( 28426849 )
2017
22
Patterns of Intermediate Uveitis in Children Presenting at a Tertiary Eye Care Center in South India. ( 28936054 )
2017
23
Risk of Ocular Complications in Patients with Noninfectious Intermediate Uveitis, Posterior Uveitis, or Panuveitis. ( 26712559 )
2016
24
Remission of Intermediate Uveitis: Incidence and Predictive Factors. ( 26772874 )
2016
25
Phenotypic changes of peripheral blood mononuclear cells upon corticosteroid treatment in idiopathic intermediate uveitis. ( 27989897 )
2016
26
Ocular Siderosis Subsequent to a Missed Pars Plana Metallic Foreign Body that Masqueraded as Refractory Intermediate Uveitis. ( 27849408 )
2016
27
Associations of Systemic Diseases with Intermediate Uveitis. ( 26786193 )
2016
28
Retinal Dystrophy in 6 Young Patients Who Presented with Intermediate Uveitis. ( 27157150 )
2016
29
Predictors of Long-Term Visual Outcome in Intermediate Uveitis. ( 28017424 )
2016
30
Peripheral Vasculitis, Intermediate Uveitis and Interferon Use in Multiple Sclerosis. ( 27800257 )
2016
31
A cross-sectional study of submacular thickening in intermediate uveitis and determination of treatment threshold. ( 27188332 )
2016
32
Use of Immunosuppressive Medications for Treatment of Pediatric Intermediate Uveitis. ( 27960602 )
2016
33
Influence of baseline demographic and clinical characteristics in the visual outcome of intermediate uveitis: a survival analysis. ( 27030281 )
2016
34
Ultra-wide Field Fluorescein Angiography in Retinitis Pigmentosa with Intermediate Uveitis. ( 27413510 )
2016
35
Bilateral intermediate uveitis with appearance of frosted branch angiitis and associated with Mycoplasma pneumoniae infection: case report and review of the literature. ( 27132140 )
2016
36
INFLIXIMAB THERAPY IN PATIENTS WITH NONINFECTIOUS INTERMEDIATE UVEITIS RESISTANT TO CONVENTIONAL IMMUNOMODULATORY THERAPY. ( 27681002 )
2016
37
Injectable Fluocinolone Acetonide Long-Acting Implant for Noninfectious Intermediate Uveitis, Posterior Uveitis, and Panuveitis: Two-Year Results. ( 27421623 )
2016
38
Chikungunya Virus Infection Manifesting as Intermediate Uveitis. ( 28010143 )
2016
39
Intermediate uveitis: an unusual presentation of cytomegalovirus intraocular infection in an immunocompetent patient. ( 25969485 )
2015
40
Benefits of Systemic Anti-inflammatory Therapy versus Fluocinolone Acetonide Intraocular Implant for Intermediate Uveitis, Posterior Uveitis, and Panuveitis: Fifty-four-Month Results of the Multicenter Uveitis Steroid Treatment (MUST) Trial and Follow-up Study. ( 26298715 )
2015
41
Discrepancy in Fluorescein Angiography and Optical Coherence Tomography Findings of Macular Edema in Intermediate Uveitis. ( 26645484 )
2015
42
Chronic candida endophthalmitis as a cause of intermediate uveitis. ( 25870216 )
2015
43
Intermediate uveitis associated with familial Mediterranean fever. ( 26487035 )
2015
44
Associations of Independent IL2RA Gene Variants with Intermediate Uveitis. ( 26133380 )
2015
45
Treatment of cystoid macular edema secondary to chronic non-infectious intermediate uveitis with an intraocular dexamethasone implant. ( 26222112 )
2015
46
Clinical characteristics of intermediate uveitis in adult Turkish patients. ( 26309876 )
2015
47
Intermediate uveitis and multiple sclerosis: to scan or not to scan. ( 26338960 )
2015
48
Possession of the HLA-DRB1*1501 Allele and Visual Outcome in Idiopathic Intermediate Uveitis. ( 25634309 )
2015
49
Analysis of a Functional IL-6 Gene Polymorphism in HLAB27 Associated and Intermediate Uveitis Gives New Insight in Disease Pathogenesis and Commonality with Other Autoimmune Diseases. ( 26640809 )
2015
50
Association analysis of TGFBR3 gene with BehAset's disease and idiopathic intermediate uveitis in a Caucasian population. ( 25677673 )
2015

Variations for Intermediate Uveitis

Expression for Intermediate Uveitis

Search GEO for disease gene expression data for Intermediate Uveitis.

Pathways for Intermediate Uveitis

Pathways related to Intermediate Uveitis according to GeneCards Suite gene sharing:

(show top 50) (show all 67)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.88 HLA-B IFNG IL10 IL2 IL2RA IL6
2
Show member pathways
13.72 CXCR3 IL10 IL2 IL2RA IL6 TGFBR3
3
Show member pathways
13.57 CXCR3 IFNG IL10 IL2 IL2RA IL6
4
Show member pathways
13.41 IFNG IL10 IL2 IL2RA IL6 TGFBR3
5
Show member pathways
13.31 CXCR3 IL10 IL2 IL2RA IL6 TNF
6
Show member pathways
13.26 HLA-B IFNG IL10 IL2 IL2RA IL6
7
Show member pathways
13.2 CXCR3 IL10 IL2 IL2RA IL6 TGFBR3
8
Show member pathways
12.94 IFNG IL10 IL2 IL6 TNF
9
Show member pathways
12.91 HLA-B IL2 IL2RA IL6 TNF
10
Show member pathways
12.8 IL2 IL2RA IL6 TNF
11 12.74 IFNG IL2 IL2RA IL6
12
Show member pathways
12.7 IFNG IL2 IL2RA TNF
13
Show member pathways
12.7 HLA-B IFNG IL2 IL2RA IL6 TNF
14
Show member pathways
12.69 HLA-B IFNG IL10 IL2 IL2RA IL6
15
Show member pathways
12.55 IFNG IL10 IL2 IL6 TNF
16 12.52 IFNG IL10 IL2 IL2RA TNF
17
Show member pathways
12.47 HLA-B IFNG IL2 TNF
18
Show member pathways
12.4 HLA-B IFNG IL10 IL2 IL2RA IL6
19
Show member pathways
12.39 IFNG IL10 IL2 IL6 TNF
20 12.38 HLA-B IL2 IL2RA IL6 TNF
21
Show member pathways
12.31 IFNG IL2 IL6 TNF
22
Show member pathways
12.27 IFNG IL10 IL2 IL2RA IL6 TNF
23
Show member pathways
12.24 IFNG IL6 TNF
24 12.22 IFNG IL10 IL6 TNF
25 12.21 HLA-B IFNG IL10
26
Show member pathways
12.2 IFNG IL6 TNF
27
Show member pathways
12.2 IL10 IL2 IL6 TNF
28
Show member pathways
12.2 IFNG IL10 IL2 IL6 TNF
29
Show member pathways
12.18 IFNG IL10 TNF
30
Show member pathways
12.12 IFNG IL6 TNF
31 12.11 IFNG IL6 TNF
32 12.11 IL10 IL6 TNF
33
Show member pathways
12.05 IFNG IL10 IL2 IL2RA IL6
34
Show member pathways
12.01 IFNG IL2 IL2RA
35 12 IFNG IL2 IL6 TNF
36 11.94 IL10 IL6 TNF
37
Show member pathways
11.93 IFNG IL2 IL2RA
38 11.88 IFNG IL10 IL6 TNF
39 11.87 IL2RA IL6 TNF
40 11.83 IFNG IL6 TNF
41 11.8 IFNG IL10 IL2 IL2RA IL6
42 11.79 IFNG IL2 IL6
43 11.75 IL10 IL6 TNF
44
Show member pathways
11.75 IFNG IL2 IL2RA TNF
45 11.7 IFNG IL10 IL2 IL2RA IL6 TNF
46
Show member pathways
11.66 IFNG IL2 IL6 TNF
47
Show member pathways
11.63 IFNG IL2 IL2RA TNF
48 11.62 IFNG TGFBR3 TNF
49 11.59 IFNG IL10 IL2 IL6 TNF
50 11.54 IL10 IL6 TNF

GO Terms for Intermediate Uveitis

Cellular components related to Intermediate Uveitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.73 IFNG IL10 IL2 IL6 TGFBR3 TNF
2 extracellular space GO:0005615 9.63 IFNG IL10 IL2 IL6 TGFBR3 TNF
3 external side of plasma membrane GO:0009897 9.26 CXCR3 IL2RA TGFBR3 TNF
4 cell surface GO:0009986 9.02 CXCR3 HLA-B IL2RA TGFBR3 TNF

Biological processes related to Intermediate Uveitis according to GeneCards Suite gene sharing:

(show all 35)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of protein phosphorylation GO:0001934 9.81 IFNG IL2 TNF
2 cellular response to lipopolysaccharide GO:0071222 9.79 IL10 IL6 TNF
3 positive regulation of DNA binding transcription factor activity GO:0051091 9.77 IL10 IL6 TNF
4 negative regulation of inflammatory response GO:0050728 9.75 IL10 IL2 IL2RA
5 regulation of signaling receptor activity GO:0010469 9.72 IFNG IL10 IL2 IL6 TNF
6 positive regulation of tyrosine phosphorylation of STAT protein GO:0042531 9.7 IFNG IL2 IL6
7 response to glucocorticoid GO:0051384 9.69 IL10 IL6 TNF
8 negative regulation of mitotic cell cycle GO:0045930 9.67 IL10 TNF
9 positive regulation of T cell proliferation GO:0042102 9.67 IL2 IL2RA IL6
10 positive regulation of cytokine secretion GO:0050715 9.66 IL10 TNF
11 protein import into nucleus, translocation GO:0000060 9.66 IFNG TNF
12 negative regulation of interleukin-6 production GO:0032715 9.65 IL10 TNF
13 positive regulation of activated T cell proliferation GO:0042104 9.65 IL2 IL2RA
14 positive regulation of protein complex assembly GO:0031334 9.65 IFNG TNF
15 humoral immune response GO:0006959 9.65 IFNG IL6 TNF
16 inflammatory response GO:0006954 9.65 CXCR3 IL10 IL2RA IL6 TNF
17 positive regulation of osteoclast differentiation GO:0045672 9.64 IFNG TNF
18 positive regulation of chemokine production GO:0032722 9.63 IL6 TNF
19 positive regulation of T cell differentiation GO:0045582 9.63 IL2 IL2RA
20 positive regulation of membrane protein ectodomain proteolysis GO:0051044 9.62 IFNG TNF
21 negative regulation of growth of symbiont in host GO:0044130 9.61 IL10 TNF
22 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.61 IL10 TNF
23 positive regulation of immunoglobulin secretion GO:0051024 9.6 IL2 IL6
24 interleukin-2-mediated signaling pathway GO:0038110 9.58 IL2 IL2RA
25 negative regulation of lipid storage GO:0010888 9.57 IL6 TNF
26 endothelial cell apoptotic process GO:0072577 9.56 IL10 TNF
27 negative regulation of cytokine secretion involved in immune response GO:0002740 9.55 IL10 TNF
28 cytokine-mediated signaling pathway GO:0019221 9.55 IL10 IL2 IL2RA IL6 TNF
29 negative regulation of lymphocyte proliferation GO:0050672 9.54 IL2 IL2RA
30 receptor biosynthetic process GO:0032800 9.46 IL10 TNF
31 regulation of T cell homeostatic proliferation GO:0046013 9.43 IL2 IL2RA
32 positive regulation of calcidiol 1-monooxygenase activity GO:0060559 9.4 IFNG TNF
33 positive regulation of vitamin D biosynthetic process GO:0060557 9.37 IFNG TNF
34 immune response GO:0006955 9.23 HLA-B IFNG IL10 IL2 IL2RA IL6
35 regulation of regulatory T cell differentiation GO:0045589 9.13 IFNG IL2 IL2RA

Molecular functions related to Intermediate Uveitis according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.13 IL10 IL2 IL6
2 cytokine activity GO:0005125 9.02 IFNG IL10 IL2 IL6 TNF

Sources for Intermediate Uveitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....